| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1 Harvard Skin Disease Research Center, Department of Dermatology; 2 Department of Pathology, Brigham and Women’s Hospital, and 3 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
Prostate tumor cells preferentially adhere to bone marrow endothelial cells (BMECs) compared with endothelial linings from other tissue microvessels, implicating the importance of BMEC adhesion in the predilection of prostate tumor metastasis to bone. E (endothelial)-selectin, which functions as an initiator of leukocyte adhesion to target tissue endothelium, is constitutively expressed on BMECs, suggesting that prostate tumor cells could use this adhesive mechanism to initiate their migration into bone. In this report, we demonstrate for the first time that human bone-metastatic prostate tumor cells roll on human BMECs under physiological flow conditions. We show that these dynamic adhesive interactions are dependent on the expression of BMEC E-selectin and sialylated glycoconjugates on bone-metastatic prostate tumor cells. We also establish the importance of both glycoprotein(s) and glycosphingolipid structures displaying sialyl Lewis X epitopes as potential E-selectin ligands on bone-metastatic prostate tumor cells. Coexpression of sialylated glycoproteins and glycolipids on bone-metastatic prostate tumor cells triggers robust E-selectin binding activity, which is identical to that observed on human hematopoietic progenitor cells. By Western blot analysis, we identify candidate E-selectin glycoprotein ligand(s); distinct sialyl Lewis X (or HECA-452 antigen)-bearing membrane proteins were resolved at Mr 130,000 and Mr 220,000 as well as others ranging from Mr 100,000 to Mr 220,000. Immunohistochemical analysis of HECA-452 antigen expression on normal prostate tissue and on low- and high-grade prostate adenocarcinoma shows that HECA-452 antigen expression is directly associated with prostate tumor progression and may indicate acquisition of E-selectin ligand expression. These findings provide novel insight into potential adhesive mechanisms promoting hematogenous dissemination of prostate tumor cells into bone.
This article has been cited by other articles:
|
|
 |
|
  S. R Barthel, J. D Gavino, G. K Wiese, J. M Jaynes, J. Siddiqui, and C. J Dimitroff Analysis of glycosyltransferase expression in metastatic prostate cancer cells capable of rolling activity on microvascular endothelial (E)-selectin Glycobiology, October 1, 2008; 18(10): 806 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Strewler Cancer Stem Cells and Bone Metastasis IBMS BoneKEy, September 1, 2008; 5(9): 308 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Gainers, L. Descheny, S. R. Barthel, L. Liu, M.-A. Wurbel, and C. J. Dimitroff Skin-Homing Receptors on Effector Leukocytes Are Differentially Sensitive to Glyco-Metabolic Antagonism in Allergic Contact Dermatitis J. Immunol., December 15, 2007; 179(12): 8509 - 8518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Langley and I. J. Fidler Tumor Cell-Organ Microenvironment Interactions in the Pathogenesis of Cancer Metastasis Endocr. Rev., May 1, 2007; 28(3): 297 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Garcia, N. Callewaert, and L. Borsig P-selectin mediates metastatic progression through binding to sulfatides on tumor cells Glycobiology, February 1, 2007; 17(2): 185 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gout, C. Morin, F. Houle, and J. Huot Death Receptor-3, a New E-Selectin Counter-Receptor that Confers Migration and Survival Advantages to Colon Carcinoma Cells by Triggering p38 and ERK MAPK Activation. Cancer Res., September 15, 2006; 66(18): 9117 - 9124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Burdick, J. T. Chu, S. Godar, and R. Sackstein HCELL Is the Major E- and L-selectin Ligand Expressed on LS174T Colon Carcinoma Cells J. Biol. Chem., May 19, 2006; 281(20): 13899 - 13905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Strewler The Stem Cell Niche and Bone Metastasis IBMS BoneKEy, May 1, 2006; 3(5): 19 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. F. Costa, M. Balcells, E. R. Edelman, L. M. Nadler, and A. A. Cardoso Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-{kappa}B Blood, January 1, 2006; 107(1): 285 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Dimitroff Sharing the Same Vascular Addressins for Osteotropic Behavior of Hematopoietic Progenitor Cells and Cancer IBMS BoneKEy, October 1, 2005; 2(10): 16 - 19. [Full Text] [PDF]
|
|
|
|
|
|
C. J. Dimitroff, L. Descheny, N. Trujillo, R. Kim, V. Nguyen, W. Huang, K. J. Pienta, J. L. Kutok, and M. A. Rubin Identification of Leukocyte E-Selectin Ligands, P-Selectin Glycoprotein Ligand-1 and E-Selectin Ligand-1, on Human Metastatic Prostate Tumor Cells Cancer Res., July 1, 2005; 65(13): 5750 - 5760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. D. Hanley, M. M. Burdick, K. Konstantopoulos, and R. Sackstein CD44 on LS174T Colon Carcinoma Cells Possesses E-Selectin Ligand Activity Cancer Res., July 1, 2005; 65(13): 5812 - 5817. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
